Lupus ABC spearheading a new era of collaboration to advance lupus drug development

Despite having a robust drug development pipeline, lupus remains far behind other rheumatic and autoimmune conditions for which dozens of targeted therapies have been developed. Addressing the pervasive, long-standing challenges impeding the field requires a paradigm shift and a patient-powered, community-wide approach, exemplified by the Lupus Accelerating Breakthroughs Consortium (Lupus ABC).